<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6527">
  <stage>Registered</stage>
  <submitdate>14/11/2016</submitdate>
  <approvaldate>14/11/2016</approvaldate>
  <nctid>NCT02967731</nctid>
  <trial_identification>
    <studytitle>480 Biomedical Sinus Drug Depot</studytitle>
    <scientifictitle>An Exploratory Safety Study of 480 Biomedical Sinus Drug Depot in Adult Subjects With Chronic Sinusitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>480MFSDD2016-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Sinusitis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 480 Mometasone Furoate Sinus Drug Depot

Experimental: 480 Mometasone Furoate Sinus Drug Depot - 480 Mometasone Furoate Sinus Drug Depot


Treatment: drugs: 480 Mometasone Furoate Sinus Drug Depot
Management of Chronic Sinusitis

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Product related serious adverse events from baseline visit to 4 weeks post procedure</outcome>
      <timepoint>4 weeks post procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Mometasone Furoate concentration level from pre-treatment to end of treatment</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of CS.

          -  Female study subjects of child-bearing potential must have a negative pregnancy test
             and must agree to not become pregnant during the course of the study.

          -  The study subject has been informed of the nature of the study, agrees to its
             provisions and has provided written informed consent as approved by the ethics
             committee of the respective clinical site.

          -  The study subject agrees to comply with all study requirements</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known history of intolerance to corticosteroids.

          -  Oral-steroid dependent condition.

          -  Having had corticosteroids with potential systemic effect (e.g., oral, parenteral, or
             high dose topical) 1 month prior to screening visit.

          -  Subjects with acute or chronic intracranial or orbital complications of chronic
             rhinosinusitis (e.g., brain abscess, related problems with eyes or central nervous
             system).

          -  Known history of hypothalamic pituitary adrenal (HPA) axial dysfunction or having
             morning serum cortisol level at screening outside of normal range.

          -  Previous pituitary or adrenal surgery.

          -  History or diagnosis (in either eye) of glaucoma, ocular hypertension, or cataracts.

          -  Recent participation in another clinical trial within 1 month of screening visit.

          -  Subjects currently participating in an investigational drug or device study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>6/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Queen Elizabeth Hospital - Adelaide</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Monash Medical Center - Melbourne</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>480 Biomedical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase I, exploratory safety study of the 480 Biomedical Mometasone Furoate Sinus
      Drug Depot in adult subjects with chronic sinusitis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02967731</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Veronica Faughnan</name>
      <address />
      <phone>617-393-4600</phone>
      <fax />
      <email>vfaughnan@480biomedical.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>